[{"address1": "60 Jubilee Avenue", "address2": "Milton Park", "city": "Abingdon", "zip": "OX14 4RX", "country": "United Kingdom", "phone": "44 12 3543 0000", "website": "https://www.adaptimmune.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.", "fullTimeEmployees": 506, "companyOfficers": [{"maxAge": 1, "name": "Mr. Adrian G.  Rawcliffe", "age": 52, "title": "CEO & Director", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 1043255, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William Charles A. Bertrand Jr., Esq., J.D.", "age": 59, "title": "COO, Chief Compliance Officer & Secretary", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 703097, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Helen Katrina Tayton-Martin MBA, Ph.D.", "age": 57, "title": "Co-Founder", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 677404, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher James Hill ACA, BA (Hons)", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juli P. Miller Ph.D.", "title": "VP of Corporate Affairs & Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kerry  Sharp", "title": "Senior VP & General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Dana  Lynch", "title": "Senior Director of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kimberly  Freeman", "title": "Vice President of Commercial Planning", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Laura  Gunn", "title": "Vice President of Medical Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.0, "open": 0.0666, "dayLow": 0.0549, "dayHigh": 0.0549, "regularMarketPreviousClose": 0.0, "regularMarketOpen": 0.0666, "regularMarketDayLow": 0.0549, "regularMarketDayHigh": 0.0549, "payoutRatio": 0.0, "beta": 2.492, "forwardPE": -0.110240966, "volume": 48742230, "regularMarketVolume": 48742230, "averageVolume": 101200215, "averageVolume10days": 15692623, "averageDailyVolume10Day": 15692623, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 14551333, "fiftyTwoWeekLow": 0.0202, "fiftyTwoWeekHigh": 0.8334, "allTimeHigh": 21.57, "allTimeLow": 0.0202, "priceToSalesTrailing12Months": 0.2235743, "fiftyDayAverage": 0.100406, "twoHundredDayAverage": 0.24499275, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": "NaN", "currency": "USD", "tradeable": false, "enterpriseValue": 108336688, "profitMargins": -2.6082199, "floatShares": 1218590593, "sharesOutstanding": 265051591, "sharesShort": 31376776, "sharesShortPriorMonth": 23052335, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.1184, "heldPercentInsiders": 0.0063099996, "heldPercentInstitutions": 0.31233, "shortRatio": 0.19, "shortPercentOfFloat": 0.1434, "impliedSharesOutstanding": 226172000, "bookValue": -0.268, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -169756000, "trailingEps": -0.66, "forwardEps": -0.38, "enterpriseToRevenue": 1.665, "enterpriseToEbitda": -0.789, "52WeekChange": -0.9593496, "SandP52WeekChange": 0.1198014, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ADAP", "underlyingSymbol": "ADAP", "shortName": "Adaptimmune Therapeutics plc", "longName": "Adaptimmune Therapeutics plc", "firstTradeDateEpochUtc": 1430919000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d9a36f50-8d36-3b28-b886-83aa23ac2f63", "messageBoardId": "finmb_113495056", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.0549, "targetHighPrice": 1.5, "targetLowPrice": 0.09, "targetMeanPrice": 0.68333, "targetMedianPrice": 0.46, "recommendationMean": 3.33333, "recommendationKey": "hold", "numberOfAnalystOpinions": 3, "totalCash": 26061000, "totalCashPerShare": 0.016, "ebitda": -137240992, "totalDebt": 48680000, "quickRatio": 1.067, "currentRatio": 1.516, "totalRevenue": 65085000, "revenuePerShare": 0.252, "returnOnAssets": -0.40862998, "returnOnEquity": -13.410971, "grossProfits": -63606000, "freeCashflow": -123189752, "operatingCashflow": -190027008, "revenueGrowth": -0.893, "grossMargins": -0.97727996, "ebitdaMargins": -2.10864, "operatingMargins": -2.21452, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-11-08"}]